Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Production / Operations

Microbix Commercializes SARS-CoV-2 (COVID) Recombinant Antigen For Usage in QAPs and Test Manufacturing

By The Northwire Desk — AI Analysis Jan 07, 2026 · 07:00 MBX · 0.245 MICROBIX BIOSYSTEMS INC. J
MBX · Price

Executive Summary

  • Microbix Biosystems announces the first commercial recombinant SARS‑CoV‑2 nucleocapsid antigen, now available at scale for its quality assessment products (QAPs™).
  • The recombinant antigen is incorporated into PROCEEDx® (RUO) and REDx® (IVD) QAP lines, supporting proficiency testing and external quality assessment programs worldwide.
  • The new product expands Microbix’s portfolio beyond native antigens, improves supply‑chain security, and targets a growing market for antigen‑based COVID‑19 testing; QAP sales totaled C$5.6 million in fiscal 2025.

Key Details

  • Product: Recombinant nucleocapsid protein of SARS‑CoV‑2 (COVID‑19) – first commercial recombinant antigen from Microbix.
  • Usage: Integrated into Microbix’s QAPs™ for clinical laboratory proficiency testing (PT/EQA) and incorporated in PROCEEDx® (RUO) and REDx® (IVD) branded QAPs.
  • Scale: Developed, manufactured at commercial scale, and fully validated; now available to test manufacturers and laboratories globally.
  • Strategic Benefit: Enhances supply‑chain security, reduces cost exposure, and diversifies Microbix’s antigen production capability (native vs. recombinant).
  • Market Context: Ongoing demand for SARS‑CoV‑2 antigen testing as the virus remains endemic; QAPs related to COVID‑19 represent a meaningful portion of total QAP sales (C$5.6 M FY2025).
  • Company Background: Microbix reported C$18.6 million revenue in fiscal 2025 with >120 employees; ISO 9001 & 13485 accredited, FDA registered, CE marked, and operating in over 30 countries.
  • Leadership Quote: Dr. Mark Luscher (SVP Scientific Affairs) highlighted the new recombinant platform as “another tool for delivering on our commitment to meet the demanding technical requirements of the diagnostic industry.”

Notable Quotes

“Our teams have deep expertise in making antigen products that have the properties needed to measure and characterize the disease response… With this, we have added yet another tool for delivering on our commitment to meet the demanding technical requirements of the diagnostic industry.” – Dr. Mark Luscher, SVP Scientific Affairs

Materiality Assessment: Material – Positive (introduces a new revenue‑generating product line with strategic supply‑chain benefits).

Read the original news release →

More from MICROBIX BIOSYSTEMS INC. J

May 14, 2026 · 08:01

Microbix Revenue Plunges on China Sales Collapse; Cash Burn Concerns Mount Despite Q2 Stabilization

Earnings Apr 27, 2026 · 07:00

Microbix Product Validation Fails to Offset Revenue Decline and Cash Burn Concerns

Other Apr 15, 2026 · 07:00

Microbix Biosystems Showcases HCV Mimetic as Revenue Contracts Shrink and Cash Burn Accelerates

Other Mar 17, 2026 · 07:00

Microbix Presents Reference-Material Innovations at EUROGIN

Drill Results Mar 10, 2026 · 16:13

Microbix partner Sequel continues work on Kinlytic

Production / Operations Mar 10, 2026 · 07:00

Microbix's Clot-Buster Drug Project Advances

Production / Operations